Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 11/20 | 0.91 |
| ▸ | KCNK9 | Q9NPC2 | 9/20 | 0.91 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 3/20 | 0.71 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17620462 | 0.94 | KCNK3 (0.91) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL28816526 | 0.89 | KCNK3 (0.73) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL4253897 | 0.89 | KCNK3 (0.93) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL3675463 | 0.89 | KCNK3 (0.84) | KCNK3KCNK9MEN1KMT2ARXFP1 | |
| SCHEMBL4250050 | 0.86 | NPC1 (0.73) | KCNK3KCNK9MEN1KMT2ANPC1 | |
| SCHEMBL4248711 | 0.86 | KCNK3 (0.81) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL30462972 | 0.86 | NPC1 (0.73) | KCNK3KCNK9MEN1KMT2ANPC1 | |
| SCHEMBL2105158 | 0.84 | KCNK3 (0.79) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL21377679 | 0.84 | KCNK3 (0.84) | KCNK3KCNK9KCNH2MEN1KMT2A | |
| SCHEMBL259666 | 0.83 | KCNK3 (0.87) | KCNK3KCNK9KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312160-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-2794565-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160168132-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2016-06-16 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| US-8507546-B2 | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2013-08-13 | — | — | US | disclosed |
| WO-2013096744-A1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2012-11-01 | — | — | US | disclosed |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) | 2012-11-01 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | CENIX BIOSCIENCE GMBH (DE) | 2009-12-31 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
| WO-2009016088-A1 | THE USE OF BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | WO | disclosed |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324580-A1 | Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases | SCARB1, MSR1, HAVCR2 | KCNK3 4636/4885KCNK9 4781/4885KCNH2 4853/4885 |
| US-20120276121-A1 | USE OF INHIBITORS OF SCAVENGER RECEPTOR CLASS PROTEINS FOR THE TREATMENT OF INFECTIOUS DISEASES | SCARB1, MSR1, HAVCR2 | KCNK3 4636/4885KCNK9 4781/4885KCNH2 4853/4885 |
| US-20090036420-A1 | BENZAMIDE DERIVATIVES AND THEIR USE FOR TREATING CNS DISORDERS | GABBR1, GABBR2, CHRM2 | KCNK3 1019/4885KCNK9 1229/4885KCNH2 302/4885 |
| US-20160168132-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | GLB1, GBA1, GALC | KCNK3 1770/4885KCNK9 1807/4885KCNH2 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.